NEW YORK (GenomeWeb) – Australian biotech firm Reproductive Health Science said that it has signed a three-year exclusive agreement with Tani Medikal for the distribution of RHS's EmbryoCellect kit for pre-implantation genetic screening for in vitro fertilization.

Tani Medikal is based in Turkey and will distribute EmbryoCellect in Turkey, Azerbaijan, Georgia, Turkish Republic of Northern Cyprus, Kosovo, Macedonia, and North Iraq (Kurdish region).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.